Eli Casdin - Jun 28, 2024 Form 4 Insider Report for STANDARD BIOTOOLS INC. (LAB)

Signature
/s/ Eli Casdin by Agnieszka Gallagher, Attorney-in-Fact
Stock symbol
LAB
Transactions as of
Jun 28, 2024
Transactions value $
$0
Form type
4
Date filed
7/2/2024, 05:17 PM
Previous filing
Jun 27, 2024
Next filing
Jul 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LAB Common Stock Award $0 +43.1K +1.59% $0.00 2.75M Jun 28, 2024 Direct F1, F2
holding LAB Common Stock 13.9M Jun 28, 2024 Casdin Private Growth Equity Fund II, L.P. F3
holding LAB Common Stock 2.74M Jun 28, 2024 By Casdin Private Growth Equity Fund, L.P. F4
holding LAB Common Stock 18.9K Jun 28, 2024 See footnote F5
holding LAB Common Stock 46.7M Jun 28, 2024 Casdin Partners Master Fund, L.P F6
holding LAB Common Stock 545K Jun 28, 2024 Casdin Amplify Fund, LP F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LAB Stock Option (Right to buy) Award $0 +72.2K $0.00 72.2K Jun 28, 2024 Common Stock 72.2K $1.77 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Restricted Stock Units ("RSUs") that vest in full on the earlier to occur of June 28, 2025 and one day prior to the date of the Company's next annual meeting of stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.
F2 Includes 2,604,060 shares of common stock received in a pro rata distribution for no consideration by C-LSH II LLC in accordance with the exemptions afforded by Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F3 The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F4 The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
F5 The securities are indirectly owned by Eli Casdin who has voting and investment discretion with respect to the securities.
F6 The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP.
F7 The securities are owned directly by Casdin Amplify Fund, LP ("Amplify") and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin and the GP.
F8 The Option becomes exercisable in twelve equal monthly installments beginning on July 28, 2024, subject to the Reporting Person's continued service through the applicable vesting date.

Remarks:

The Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.